Adverse bone effects of medications used to treat non-skeletal disorders.

about

Adverse bone effects of medications used to treat non-skeletal disorders.

Item

http://www.wikidata.org/entity/Q48332195

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Adverse bone effects of medications used to treat non-skeletal disorders.

@en

Adverse bone effects of medications used to treat non-skeletal disorders.

@nl

type

Item

label

Adverse bone effects of medications used to treat non-skeletal disorders.

@en

Adverse bone effects of medications used to treat non-skeletal disorders.

@nl

prefLabel

Adverse bone effects of medications used to treat non-skeletal disorders.

@en

Adverse bone effects of medications used to treat non-skeletal disorders.

@nl

P1476

Adverse bone effects of medications used to treat non-skeletal disorders.

@en

P2093

N B Watts

http://www.w3.org/2001/XMLSchema#string

P2860

The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5).

Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception.

Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide.

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Hyponatremia-induced osteoporosis.

Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.

P2888

s00198-017-4171-4

P304

2741-2746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-017-4171-4

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nelson B Watts

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28752332

http://www.w3.org/2001/XMLSchema#string